Loading...
•
Mar 31, 2024
PDS Biotechnology Q1 2024 Earnings Report
PDS Biotechnology reported a net loss for Q1 2024, increased R&D expenses, and provided updated data from the Phase 2 VERSATILE-002 clinical trial.
Key Takeaways
PDS Biotechnology reported a net loss of $10.6 million for the first quarter of 2024, compared to a net loss of $9.7 million for the same period in 2023. R&D expenses increased to $6.7 million, and the company announced positive, updated data from its Phase 2 VERSATILE-002 clinical trial.
Reported a net loss of $10.6 million, or $0.30 per share.
R&D expenses increased to $6.7 million due to higher clinical study and medical affairs costs.
Announced updated results from the VERSATILE-002 Phase 2 trial, showing promising outcomes in HNSCC patients.
Strengthened management with the addition of Stephan Toutain as Chief Operating Officer.
Forward Guidance
PDS Biotechnology plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced head and neck squamous cell cancers (HNSCC).
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...